LeMaitre Vascular, Inc.
General ticker "LMAT" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $2.0B (TTM average)
LeMaitre Vascular, Inc. follows the US Stock Market performance with the rate: 29.0%.
Estimated limits based on current volatility of 1.5%: low 90.63$, high 93.45$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-05-21, amount 0.25$ (Y1.09%)
- Total employees count: 664 (+5.4%) as of 2024
- US accounted for 58.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Acquisition/divestiture risks, Pricing pressure, Market acceptance, Regulatory and compliance
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [69.99$, 102.43$]
- 2026-12-31 to 2027-12-31 estimated range: [75.09$, 108.54$]
Financial Metrics affecting the LMAT estimates:
- Negative: with PPE of 35.2 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 27.21 > 18.39
- Positive: Interest expense per share per price, % of 0.27 <= 0.73
- Positive: 42.59 < Shareholder equity ratio, % of 63.91 <= 64.29
- Negative: Industry inventory ratio change (median), % of 1.78 > 0.28
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.57 > 6.06
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 1.51
- Positive: -0.02 < Operating cash flow per share per price, % of 4.28
Short-term LMAT quotes
Long-term LMAT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $193.48MM | $219.86MM | $249.60MM |
| Operating Expenses | $156.77MM | $167.61MM | $181.69MM |
| Operating Income | $36.71MM | $52.26MM | $67.91MM |
| Non-Operating Income | $2.76MM | $4.62MM | $7.27MM |
| Interest Expense | $0.00MM | $0.20MM | $5.18MM |
| R&D Expense | $16.97MM | $15.65MM | $14.14MM |
| Income(Loss) | $39.48MM | $56.88MM | $75.18MM |
| Taxes | $9.37MM | $12.84MM | $17.45MM |
| Net Income(Loss)* | $30.11MM | $44.04MM | $57.73MM |
| Stockholders Equity | $297.90MM | $337.29MM | $393.52MM |
| Inventory | $52.33MM | $55.94MM | $70.42MM |
| Assets | $346.78MM | $551.82MM | $615.69MM |
| Operating Cash Flow | $36.75MM | $44.12MM | $81.25MM |
| Capital expenditure | $7.26MM | $6.96MM | $6.78MM |
| Investing Cash Flow | $-24.71MM | $-200.12MM | $-64.94MM |
| Financing Cash Flow | $-7.13MM | $158.10MM | $-14.54MM |
| Earnings Per Share** | $1.36 | $1.96 | $2.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.